Open AccessContinued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load
Author(s) -
Juan A. Arnaiz,
Josép Mallolas,
Daniel Podzamczer,
Jan Gerstoft,
Jens D. Lundgren,
Pedro Cahn,
Gerd Fätkenheuer,
A d'Arminio-Monforte,
A Casiró,
Peter Reiss,
David M. Burger,
Michael Stek,
José M. Gatell
Publication year - 2003
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/00002030-200304110-00008
Subject(s) - indinavir , viral load , ritonavir , medicine , regimen , clinical endpoint , gastroenterology , virology , human immunodeficiency virus (hiv) , randomized controlled trial , antiretroviral therapy
To compare continued indinavir (IDV) 8-hourly (q8h) with switching to indinavir/ritonavir (IDV/RTV) 12-hourly (q12h) in HIV-positive patients having suppressed viral load with IDV q8h plus two nucleoside reverse transcriptase inhibitors (NRTI).